Encellin announces new phase 1 clinical progress at ISSCR 2026 showing early evidence of non-fibrotic engraftment of cell therapy implant for type 1 diabetes
Reports and Proceedings
Updates every hour. Last Updated: 30-Oct-2026 20:15 ET (31-Oct-2026 00:15 GMT/UTC)
The Serum Institute of India (SII) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) have signed a licensing agreement covering clinical testing and future access for an SII-developed monoclonal antibody treatment (formerly known as VIS513) against dengue. With this agreement finalized, a Phase III clinical trial led by DNDi is expected to begin in the first quarter of 2027 across Malaysia, Thailand, and Brazil, all home to leading public health institutions that are members of the Dengue Alliance, a global partnership of dengue-endemic countries working to develop effective and accessible treatments. 1,000 participants are expected to join the study across the three countries.
TAPIR increases protein production in a targeted manner – with new insights into stem cell biology and disease-relevant processes.